<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006111</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068123</org_study_id>
    <secondary_id>FRE-FNCLCC-97015</secondary_id>
    <secondary_id>EU-20009</secondary_id>
    <nct_id>NCT00006111</nct_id>
  </id_info>
  <brief_title>Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract</brief_title>
  <official_title>Multicenter Study of the Quality of Life of Patients With Invasive Urothelial Cancer Treated With Conservative Surgery Followed by Cisplatin, Fluorouracil and Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Combining surgery with chemotherapy and radiation therapy may be an effective way to treat&#xD;
      cancer of the urinary tract.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining surgery, chemotherapy and&#xD;
      radiation therapy in treating patients who have stage II, stage III, or stage IV cancer of&#xD;
      the urinary tract .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the quality of life of patients with invasive stage II, III, or IV&#xD;
      carcinoma of the urothelium treated with conservative surgery plus cisplatin, fluorouracil,&#xD;
      and radiotherapy. II. Determine the efficacy of this regimen, in terms of local control, in&#xD;
      these patients. III. Determine survival of patients treated with this regimen. IV. Determine&#xD;
      the toxic effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to tumor type (T2-4a,&#xD;
      N0, M0; potentially resectable; no contraindication to surgery vs T2-4b, N0 or N1 or pN1, M0;&#xD;
      refused surgery or medical contraindications to surgery). (Accrual for stratum I was&#xD;
      completed as of 10/23/2001.) Stratum I (resectable disease): Regimen A: Patients undergo&#xD;
      radiotherapy 5 days a week for 5 weeks. Patients also receive fluorouracil IV continuously&#xD;
      and cisplatin IV continuously on days 1-4 during weeks 1 and 4. If complete response is&#xD;
      achieved by week 5, patients proceed to regimen B. If partial response or progression is&#xD;
      observed, patients undergo cystectomy. If cystectomy is refused, patients proceed to regimen&#xD;
      B. Regimen B: Patients undergo radiotherapy 5 days a week for 2 weeks. Patients also receive&#xD;
      fluorouracil and cisplatin as in regimen A on weeks 2 and 5. (Accrual for stratum I was&#xD;
      completed as of 10/23/2001.) Stratum II (unresectable disease): Patients undergo radiotherapy&#xD;
      5 days a week for 7 weeks. Patients also receive fluorouracil and cisplatin as in regimen A&#xD;
      on weeks 1, 4, and 7. Quality of life is assessed at baseline, at 6 months, and then at 1&#xD;
      year. Patients are followed at 6-8 weeks, every 6 months for 2 years, and then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 75 patients (35 for stratum I and 40 for stratum II) will be&#xD;
      accrued for this study. (Accrual for stratum I was completed as of 10/23/2001.)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1999</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <condition>Urethral Cancer</condition>
  <arm_group>
    <arm_group_label>resectable disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>unresectable disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>resectable disease</arm_group_label>
    <arm_group_label>unresectable disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>resectable disease</arm_group_label>
    <arm_group_label>unresectable disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>resectable disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>resectable disease</arm_group_label>
    <arm_group_label>unresectable disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed stage II, III, or IV carcinoma of the&#xD;
        urothelium infiltrating muscle Primary OR After development of a superficial tumor T2-T4b&#xD;
        with or without lymph node involvement and no detectable metastases No epidermoid cancer or&#xD;
        adenocarcinoma No extrapelvic lymph node involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: WHO 0-2 Life expectancy: More&#xD;
        than 6 months Hematopoietic: WBC greater than 4,000/mm3 Platelet count greater than&#xD;
        100,000/mm3 Neutrophil count greater than 1,500/mm3 Hemoglobin greater than 10 g/dL&#xD;
        Hepatic: Not specified Renal: Creatinine less than 1.5 mg/dL Other: Not pregnant Fertile&#xD;
        patients must use effective contraception during and for 2 months after study No other&#xD;
        prior malignancy except nonmelanomatous skin cancer or carcinoma in situ of the cervix No&#xD;
        prior serious illness of the gastrointestinal tract (e.g., rectal bleeding or&#xD;
        diverticulosis with complications) No contraindication to fluorouracil, cisplatin, or&#xD;
        radiotherapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior&#xD;
        chemotherapy except intravesicular instillations Endocrine therapy: Not specified&#xD;
        Radiotherapy: No prior radiotherapy Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Leon Lagrange, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. - Hopital Gaston Doumergue</name>
      <address>
        <city>Nimes</city>
        <zip>30006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35064</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92211</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General de Saint Nazaire</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>February 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2004</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>anterior urethral cancer</keyword>
  <keyword>posterior urethral cancer</keyword>
  <keyword>urethral cancer associated with invasive bladder cancer</keyword>
  <keyword>metastatic transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>regional transitional cell cancer of the renal pelvis and ureter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

